Poster

Design and rationale for a phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF

Toby M. Maher, Marlies Wijsenbeek, Michael Kreuter, Aryeh Fischer, Sinae Kim, Aditya Patel, Walid Elsharkawi.

Poster

Design and rationale for a phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with progressive pulmonary fibrosis: ALOFT-PPF

Fernando J. Martinez, Tamera J. Corte, Vincent Cottin, Aryeh Fischer, Sinae Kim, Aditya Patel, Mudiaga Sowho.

Poster

Variability of Criteria Used to Confirm Progressive Pulmonary Fibrosis: Results from a Real-World Survey

Pooja Chopra, Rebecca Hardy-Woods, Mark Small, Lisa Lancaster.